Small Cap Feast

Small Cap Feast – 30 October 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 876

Total number of AIM Companies trading: *
* As at 23 October 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 86*

Total number of NEX Growth Market Companies trading: *
* As at 23 October 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): *

Total number of Standard List Companies trading: *
* As at 23 October 2019

Dish of the Day:

RTW Venture Fund RTW.L (Main mkt Spec Funds), NAV $153m, raised $15m. Priced at NAV. seeks to achieve positive absolute performance and superior long-term capital appreciation through forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies

Off the Menu:

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

Main Market premium
African Export-Import Bank a supranational financial institution whose purpose is to facilitate, promote and expand intra- and extra- African trade, of its potential intention to publish a registration document, the Bank hereby confirms its intention to proceed with an Initial Public Offering. The GDRs are expected to be admitted to the standard listing segment of the Official List of the FCA and to trading on the Main Market of the LSE. POSTPONED
DNEG Limited intends to apply for admission of its Shares to the premium listing segment of the Official List of the FCA and to trading on the London Stock Exchange’s main market for listed securities. The Offer will be comprised of new Shares to be issued by the Company (to raise expected gross proceeds of £150m). Admission is expected to take place in November 2019.

Breakfast Buffet

Sareum Holdings* (SAR.L) 0.36p £10.75m

Sareum’s CEO, Dr Tim Mitchell, presented data yesterday demonstrating how SDC-1802 (formerly known as SAR-20351), a novel selective TYK2/JAK1 inhibitor discovered by Sareum, significantly reduces tumour growth in disease models of cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma. The studies showed that SDC-1802 induces this anti-cancer activity through a novel immunotherapeutic mechanism of action that stimulates the local immune system to attack cancer cells.
“There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties.”

Redde (REDD.L) 114.09p £350m

AGM Statement. The first quarter’s trading of the new financial year is in line with management expectations.
The Group provides a range of accident management, incident management and legal services.
FY Jun 2020E rev, £538m, PBT £49m, PE c.9x.

Hargreaves Services (HSP.L) 238p £76.53m

The diversified group delivering services to the industrial and property sectors, will hold its Annual General Meeting later this morning. At the AGM, the Group’s Chairman, Roger McDowell, will make the following statement:
“The Board is pleased to announce that trading for the first four months of the year has been satisfactory and in line with expectations.
“The Board expects to provide a trading update in early December 2019, prior to the announcement of the Group’s interim results for the six months ending 30 November 2019 on Wednesday 29 January 2020.”

Kefi Minerals (KEFI.L) 0.722p £5.93m

Q3 ops update.
Tulu Kapi Gold Project Ethiopia— receipt of all the Government permits and independent consultants reports required for closing the Project equity financing and triggering the development of the Project. The only outstanding matter now is for the Ethiopian Government to resolve certain internal administrative matters. $242m funding plan outlined.
Saudi Arabia
· Field work commenced during Q3 at the Hawiah Exploration Licence, within the Wadi Bidah Mineral District, by the KEFI-operated joint venture, G&M, as announced on 21 June 2019.
Investor webinar 2pm today https://webcasting.brrmedia.co.uk/broadcast/5d91f4e3cbe3ca44a572e3f9

Petroneft (PTR.L) 0.775p £5.6m

Update on the Licence 67 operational plan in the Tomsk Oblast, Russian Federation .
Highlights
· Plan to bring Cheremshanskoye field in Licence 67 into production during Q1 2020.
· Exploring options to work over and re-test two wells in the Ledovoye field, also in Licence 67, during 2020.

Avingtrans (AVG.L) 261.25p £81.9m

Avingtrans plc, which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, is pleased to announce its wholly owned subsidiary, Booth Industries, has secured a £7.2 million Government contract for safety doors.
This new contract consolidates the impressive turnaround since the assets of Booth Industries were bought out of administration by Stainless Metalcraft (Metalcraft), part of Avingtrans PLC’s Process Solutions and Rotating Equipment (PSRE) division, on 10 June 2019.

Synectics (SNX.L) 140p £24.9m

Update on trading for the year ending 30 November 2019.
Results for the year ending 30 November 2019 are now anticipated to be materially below market expectations. The Group’s core Systems division, supplying Synectics’ high end proprietary surveillance systems globally, has performed well in the year so far and is expected to generate results ahead of the Board’s expectations. However, this positive momentum has been more than offset by continued weakness in the Group’s UK integration businesses in security and mobile transport.

Inspiration Healthcare (IHC.L) 60.38p £23m

The global medical technology company, today announces the launch of the CosyTherm2 neonatal controller to accompany various neonatal mattresses. The launch of the CosyTherm2 follows the successful launch of its patient warming system incorporating the AlphaCore5 controller in 2018.
The CosyTherm2 has been specifically designed for the neonatal market, using pastel colouring to blend in with the nursery surroundings of neonatal intensive care and transitional care units.

Bango (BGO.L) 133.7p £132.5m

Agreement with NHN ACE, the South Korean big data digital advertisement company. Through the partnership, global app developers can easily target their offers and promotions to high value mobile and internet users in Korea.
NHN ACE and Bango are making audiences of Korean customers who are interested in paid content available for marketing. Targeting campaigns to customers with an interest in premium apps and content enables app developers to acquire new paying users and increase in-app purchase revenues.

Tern (TERN.L) 12.5p £31.8m

The investment company specialising in the Internet of Things (“IoT”), has raised approximately £1.75 million gross at a price of 11.15 pence.
The funds raised will provide Tern with additional finance to continue implementing its strategy to acquire and maintain long-term, influential interests in high growth IoT innovators and will also provide working capital.

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.